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Abstract: Cystic fibrosis (CF) is chronic lung disease characterized by an unrelenting neutrophil-predominant airway 
inflammatory response. This inflammation leads to extracellular matrix (ECM) remodeling and eventually to the 
development of bronchiectasis. While many components of the immune response in CF have been well-characterized, 
recent data suggests that small molecules may play an important and underappreciated role in this inflammation. This 
review will examine two novel molecules: proline-glycine-proline (PGP) and high mobility group box protein-1 
(HMGB1), and their potential impact in CF lung disease. This review will provide a brief overview of CF lung disease 
and background on both HMGB1 and PGP. It will then focus on these molecules in a murine model of CF-like airway 
disease and in human biological specimens from CF individuals. Finally, this manuscript will address possible 
mechanisms for therapeutic targeting of these bioactive mediators. 
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INTRODUCTION 
  Cystic fibrosis (CF) is a common lethal genetic disease in 
persons of northern European descent, with a carrier frequency 
in this population of 1:25 and an incidence of ~1:3,000 births. 
Over 30,000 CF-affected individuals have been identified in 
the U.S., and the worldwide prevalence is estimated to be 
~70,000 [1]. CF is caused by defective function of the CFTR 
gene product named the Cystic Fibrosis Transmembrane 
conductance Regulator, or CFTR. The disease is characterized 
by abnormal transport of sodium (Na
+) and chloride (Cl
-) 
across the epithelia of many tissues, including the lungs [2]. 
This dysregulated ion transport leads to a significant reduction 
of the airway surface liquid (ASL) of epithelial cells, leading 
to worsening mucus plugging and airway inflammation. Over 
time, this pathophysiology leads to ongoing airway 
remodeling with the development of progressive bronchiecta-
sis and worsening lung ventilation/ perfusion mismatch [3]. 
These pulmonary manifestations of CF are responsible for 
substantial morbidity and disease-related mortality, with a 
median survival of approximately 37 years [4]. 
  A notable result of the loss of CFTR function is the 
development of chronic airway inflammation. The airways 
of CF patients, while normal at birth, quickly become 
inflamed and chronically colonized with characteristic 
bacterial pathogens [5]. Inherent inflammation or early 
bacterial colonization may initiate this process, with the   
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activation of TLR receptors on airway epithelia and neutrophils 
(PMNs) [6, 7] and subsequent activation of NF-kappa B-
mediated inflammatory response [8]. This, in turn, leads to the 
release of prominent levels of IL-8 and IL-1 beta in the CF 
airways [9]. As delayed mucociliary clearance continues, 
persistent bacterial colonization leads to an aggressive and 
exaggerated inflammatory response with the ongoing influx of 
PMNs into the airways. PMNs release a variety of inflammatory 
products (such as myeloperoxidase, lactoferrin, and various 
proteases) causing airway epithelial damage and extracellular 
matrix remodeling [10-12]. This release can be carefully co-
ordinated or may be as a result of PMN apoptosis or necrosis 
[13]. In addition to PMN influx, both tissue and alveolar macro-
phages are activated with airway bacterial colonization, leading 
to the release of a host of pro-inflammatory mediators [14]. 
  Although many of these components of the innate immune 
response in CF lung disease have been characterized in 
numerous studies, other inflammatory pathways have been 
suggested as having potential importance. Recently, our group 
has highlighted two inflammatory molecules, originally desc-
ribed in other conditions, which may play an important role in 
CF lung disease. Both of these molecules (proline-glycine-pro-
line (PGP) and high mobility group box-1 (HMGB1)) are found 
in an important animal model of CF-like lung disease and also 
in clinical samples from subjects with CF. Even though it is 
unknown as to how significant of a role these molecules may 
play in the overall inflammatory milieu observed in the CF 
airway, a recent publication by our group suggests that PGP is 
at least as important as IL-8 as a neutrophil chemoattractant in 
patients undergoing bronchiolitis obliterans syndrome after lung 
transplantation [15]. Similarly, in sepsis HMGB1 seems to be a 
potent and important mediator in the latter periods of this 
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PGP BACKGROUND 
  It has been known for over 30 years that digested 
collagen may have the capacity to augment both the 
inflammatory and injury response. Postlethwaite et al. 
initially described that collagen fragments derived from type 
I, II, and III collagen have the capacity to cause fibroblasts to 
migrate in vitro [16]. This group also demonstrated that type 
I collagen fragments were chemotactic for monocytes in 
vitro [17]. Senior and colleagues have also described in vitro 
neutrophil chemotaxis to sequences found in type IV 
collagen [18]. This work was extended when Riley et al. 
demonstrated an increased neutrophilic response in rats after 
intratracheal administration of collagen fragments [19]. 
However, very little work has been done in examining how 
specific motifs in collagen elicit particular inflammatory 
responses until the PGP story was delineated. 
  The story of PGP peptides and their mechanisms of 
eliciting inflammatory response had its origins in the eye. 
Alkali injury to the eye causes a profound influx of PMNs 
and it is these PMNs which drive the inflammatory response 
leading to corneal ulceration and perforation. In 1995, Pfister 
and colleagues demonstrated that alkali degradation of whole 
cornea generated two tri-peptides, N-acetyl-PGP (N--PGP) 
and N-methyl-PGP that are chemotactic for neutrophils [20]. 
Injection of these peptides into normal corneas recapitulated 
alkali eye injury [21]. Thus, specific chemotactic peptides 
for neutrophils were identified but their mechanism of action 
remained unknown. 
  Further studies from our group have identified N--PGP 
as a neutrophil chemoattractant in a murine model of 
intratracheal LPS administration. Sequence and structural 
analyses revealed a similarity between the glutamate-
leucine-arginine (ELR) positive CXC neutrophil 
chemokines, collagen fragments, and N--PGP. Chemotaxis 
experiments verified that the tripeptide is active on human 
PMNs and acts through the same CXC receptors (CXCR) as 
is well characterized for known CXCR ligands. Most 
importantly, N--PGP was detected in bronchoalveolar 
(BAL) fluid of COPD patients which had significantly 
higher concentrations of the tripeptide compared to samples 
from healthy control patients. Although not all COPD patient 
BAL fluid was positive for N--PGP, the patients who had 
elevated concentrations had radiographic evidence of 
emphysema and lower FEV1 values [22]. In all, these studies 
linked N--PGP with neutrophil influx resulting from ECM 
degradation during airway inflammation. 
  In addition to data suggesting the presence of PGP in 
clinical COPD BAL samples, our group has also 
demonstrated the presence of N--PGP and/or the non-
acetylated form of the peptide (PGP) in murine models of 
pneumonic tularemia [23] and corneal inflammation [24], 
and clinical disease samples from patients with bronchiolitis 
obliterans syndrome after lung transplantation [15] and both 
serum and sputum samples from patients with COPD [25]. 
To our knowledge, this was the first matrix-derived cellular 
chemoattractant described in clinical human specimens. 
HMGB1 BACKGROUND 
 High-mobility group box 1 (HMGB1) is an 
evolutionarily ancient protein which serves predominately as 
a deoxyribonucleic acid (DNA)-binding protein. It is 
ubiquitously expressed in the nuclear compartment of 
eukaryotic cells functioning as a transcriptional regulator via 
interaction of its A-box and B-box subunits with DNA. In 
the late 1990’s, H Wang, K Tracey and others reported that 
extracellular HMGB1 is released as a late mediator of 
inflammation in sepsis. HMGB1 was identified following 
stimulation of cultured macrophages with tumor necrosis 
factor-alpha (TNF-) and IL-1, and was verified as an active 
mediator of sepsis when blockade of the protein in mice by 
specific antibodies following LPS-mediated sepsis 
significantly reduced lethality [26]. These findings were the 
first to suggest that HMGB1 may serve as a soluble mediator 
in the modulation of inflammation. As an extracellular 
protein, HMGB1 has pleomorphic effects including 
activation of NF-kB, diffuse endothelial activation, 
hepatocellular injury, epithelial leak, and systemic activation 
of inflammatory cells [27]. HMGB1 activates inflammatory 
cells through interactions between receptor for advanced 
glycation end-products (RAGE) or toll-like receptor (TLR)-2 
and -4. As suggested by its kinetics in shock and the 
inflammatory response seen following HMGB1 challenge, 
other receptors are also activated by extracellular levels of 
HMGB1 [28], including those on neutrophils [29, 30]. 
  Although principally expressed intracellularly, the active 
extracellular form of HMGB1 is released by monocytes upon 
activation by TNF- [26, 31]. This occurs through the 
coordinated release from stimulated cells following 
acetylation of nuclear HMGB1, leading to cytoplasmic 
translocation and export via  secretory vesicles [32]. In 
addition, active HMGB1 is selectively released from necrotic 
cells, whereas cells undergoing apoptosis largely (but not 
entirely) inactivate HMGB1 during programmed cell death 
[33]. Once released, HMBG1 has been reported to have 
proinflammatory effects described above, and high levels 
have been associated with human or experimental models of 
sepsis [26], hemorrhagic shock [34], rheumatoid arthritis 
[35, 36], systemic lupus erythematosus SLE [37], and within 
the airways during ventilator induced lung injury [38]. Table 
1 summarizes characteristics of both PGP and HMGB1. 
EVALUATION OF PGP AND HMGB1 IN A CF 
ANIMAL MODEL 
  One of the challenges in developing a comprehensive 
understanding of the inflammatory milieu of the CF airway 
is lack of availability of an appropriate CF animal model that 
links CFTR dysfunction and inflammatory lung disease [1]. 
CFTR knockout mice, and mice expressing the murine 
equivalent of F508del CFTR, exhibit gastrointestinal 
morbidity and mortality reminiscent of human meconium 
ileus, however do not exhibit significant pulmonary disease 
despite the presence of the ion transport abnormality in the 
upper and lower airway. Hyperexpression of the Beta 
subunit of the epithelial sodium channel (ENaC) serves as an 
alternative murine model (termed Scnn1b+-transgenic) that 
closely resembles the pathologic findings found in the CF 
lung, including hyperabsorbtion of sodium chloride, depleted 
airway surface liquid volume, mucus obstruction and stasis, 
and airway inflammation [39]. Similar to CF lung disease in 
humans, inflammation is neutrophil predominant, and 
associated with elevated murine chemokines KC, MIP-2, and 
LIX in the lower airways [39-41]. 34    The Open Respiratory Medicine Journal, 2010, Volume 4  Gaggar et al. 
  Despite the absence of chronic bacterial colonization, the 
extent of inflammatory activation observed in the Scnn1b+ 
transgenic mouse suggest activation of innate immunity 
plays a strong role in the pathogenesis of pulmonary 
inflammation in this CF model. As such, the Scnn1b+ 
transgenic mouse serves as an important model for defining 
the role of both HMGB1 and PGP in the CF airway. 
Recapitulating observations seen in CF sputum, Scnn1b+ 
transgenic mice exhibit increased concentrations of HMGB1 
in BAL fluid supernatants by complementary assays of 
Western blot and ELISA, at concentrations known to induce 
neutrophil chemotaxis, receptor mediated proinflammatory 
effects, and observed in the serum of human sepsis subjects 
(~50 ng/mL). In addition, HMGB1 also has been shown to 
inhibit neutrophil mediated phagocytosis of apoptotic cells, 
an effect recapitulated by Scnn1b+ transgenic mouse BAL 
fluid, and blocked by inhibition of HMBG1 with neutralizing 
antibody. Moreover, intratracheal injection of wt mice with 
recombinant HMGB1 results in neutrophilic influx within 24 
hrs, and resultant production of PGP, as also observed in the 
airway secretions of CF subjects (see also below) [40]. These 
findings suggest crosstalk between neutrophilic 
proinflammatory pathways governing HMGB1 and PGP in 
the CF airway, and raise the possibility that therapeutic 
intervention into either pathway could result in beneficial 
effects. 
  One interesting question that has evolved from the 
Scnn1b+ transgenic mice data is whether HMGB1 may serve 
to directly (or indirectly) generate PGP in vivo (Fig.  1). 
While it is unlikely that PGP is directly liberated from 
collagen by HMGB1, it is entirely possible that HMGB1 
may induce the release of proteases from inflammatory cell 
populations, leading to the cleavage of PGP from intact 
collagen (Panel B). However, it is also possible that during 
necrosis of inflammatory cells, proteases are released along 
with HMGB1 and that HMGB1 has no direct influence on 
PGP production, but is rather a marker of cellular necrosis 
(Panel  A). Clarification of these points may allow for an 
improved understanding if these pathways may overlap, 
highlighting potentially interesting therapeutic targets. 
ROLE OF PGP AND HMGB1 IN CF LUNG DISEASE 
  Due to the increased PMN burden and increased matrix 
destruction observed in CF lung disease, the potential 
presence and role of PGP in this condition became of 
significant interest. In CF individuals at the beginning of 
acute pulmonary exacerbation (APE), we found that 8 out of 
Table 1.  General Features of PGP and HMGB1 
 
  PGP HMGB1 
Size  3 aminoacid peptide  30 kDa protein 
Original description  Neutrophil chemoattractant  Intracellular transcription factor 
Biological activity  Acetylated forms augments CXC receptor activation  Extracellular form activates TLR and RAGE receptors 
Clinical relevance  Sputum and serum samples of CF, COPD, and BOS  Elevated levels sepsis, hemorrhagic shock, rheumatoid arthritis, and CF 
Abbreviations: CXC: cysteine-X-cysteine chemokine; TLR: Toll-like receptor; RAGE: receptor for advanced glycation endproducts; COPD: chronic obstructive pulmonary disease; 
BOS: bronchiolitis obliterans syndrome; CF: cystic fibrosis. 
 
Fig. (1). PGP and HMGB1 in the CF airway. Two potential pathways that may link airway expression of PGP and HMGB1 are shown. 
(A): Neutrophils are recruited to the airway by inflammatory stimuli and eventually undergo necrosis. Release of HMGB1 during necrosis is 
accompanied by concurrent but independent activation of proteases MMP-9 and prolyl endopeptidase, each required for the generation of 
PGP. (B): Extracellular HMGB1 activates airway macrophages through a TLR and/or RAGE dependent pathway, resulting in the release of 
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10 individuals had both PGP and N--PGP in sputum 
samples compared to 1 out of 10 control, non-CF lung 
disease patients. In addition, through matched samples from 
individuals (n=16) at the beginning of and at the end of 
exacerbation, PGP levels declined during the course of 
inpatient hospitalization in 15 out of 16 individuals. The 
mean PGP levels went from 146 ng/ml to 80.0 ng/ml, 
although at hospital discharge levels were still 5-fold higher 
than those observed for non-CF lung disease patients. These 
results demonstrate that (a) PGP peptides are differentially 
expressed in those individuals with CF compared to those 
without CF and (b) in those CF individuals undergoing APE, 
PGP levels respond to therapy. These results suggest that 
PGP may be used as a biomarker during APE in CF lung 
disease [42]. 
  Since it was suspected that PGP was hydrolyzed and 
released from collagen, it become important to define the 
proteolytic pathways that are involved in the release of PGP 
into the extracellular environment. Previously, our group 
(and others) had shown that during APE in CF lung disease, 
there is a notable increase in proteolytic activity observed in 
airway secretions when compared to either individuals with 
stable CF lung disease or individuals without CF [43]. 
However, to our knowledge, the only protease capable of 
releasing PGP from the collagen is prolyl endopeptidase 
(PE), a cytosolic serine protease predominately described in 
neuropeptide processing and angiotensin regulation [44]. 
While PE has been described in various pulmonary cell 
populations [45, 46], both its presence extracellularly and its 
role in pulmonary related pathology (including CF) were 
unknown. 
  Despite the identification of PE as a potential protease 
involved in PGP release, due to its -propeller structure, PE 
could only act on substrates of 100 amino acids or less [47]. 
Since collagen is larger than this size restriction, liberation of 
PGP from collagen requires multiple proteases acting in 
concert. To test this hypothesis, mice were instilled 
intratracheally with various proteases known to be elevated 
in CF lung disease, either alone or in combination with PE, 
and then underwent bronchoalveolar lavage (BAL). The 
combination of MMP-9 and PE generated the largest 
quantity of PGP, with the combination of MMP-8 and PE 
also generating significant quantities. All other protease 
combinations did not generate PGP. The activities of all 
three of these proteases are elevated in CF sputum and there 
was a notable correlation between enzyme activity and PGP 
levels in clinical specimens. Due to this increased protease 
activity, when CF sputum is incubated on either type I or 
type II collagen, increased PGP levels are generated above 
those seen at baseline in CF sputum. However, when 
samples are pre-incubated with specific inhibitors of MMP-
8, MMP-9, PE or combinations of these inhibitors, PGP 
generation is inhibited by 80-100%. These results not only 
highlight the generating system of PGP in vitro and ex vivo 
but also suggest the potential of targeting the generating 
proteases as a means of abating the effects of PGP in CF 
lung disease [42]. 
  The intense neutrophilic inflammatory milieu found in 
CF, including the prominence of necrotic cells within the 
airway, strongly suggested that HMGB1 could also play an 
important role in CF airway disease, parallel to the findings 
in the Scnn1b+ transgenic mouse [48]. Indeed, levels of 
HMGB1 are elevated at baseline in CF sputum, and increase 
further during acute pulmonary exacerbation. Moreover, 
HMGB1 concentrations decrease with antimicrobial therapy 
directed at CF pathogens. Whether HMGB1 serves primarily 
as a marker of neutrophilic inflammation, or plays a direct 
pathogenic role has not yet been conclusively determined; 
however, potent effects of HMGB1, including induction of 
neutrophil chemotaxis and disruption of phagocytosis in 
vitro, and induction of lung injury in vivo, suggest it is at 
least a partial contributor to the disease [30, 40]. 
THERAPEUTIC IMPLICATIONS 
  Blockade of neutrophilic inflammation through innate 
pathways early in the pathogenesis of CF lung disease, prior 
to the onset of chronic bacterial colonization, may represent 
a strategy that obviates the potential risk of increasing 
infectious burden, as reported for a leukotriene B4 antagonist 
and methotrexate in CF individuals with moderate to 
advanced lung disease [49]. 
  The kinetics of HGMB1 as a late mediator in sepsis, and 
its identified pathogenic role in rheumatoid arthritis, 
hemorrhagic shock, and acute respiratory distress syndrome, 
make antagonism of the protein an attractive potential 
therapeutic target [50]. Several potential strategies are 
currently under study. Proof of concept studies in 
experimental models have been shown in sepsis (including 
later forms of the syndrome [51]) and hemorrhagic shock 
[52], whilst rheumatoid arthritis can be mitigated with 
antagonism of HMGB1. The corticosteroid methylprednison-
lone, known to have beneficial effects in CF lung disease 
[53], has been shown to antagonize HMGB1 [54], but is 
unlikely to be a viable option due to lack of specificity and 
excess toxicity. More specific inhibitors include anti-
HMGB1 neutralizing antibodies, and recombinant A-box 
peptide, an HMGB1 domain that antagonizes the 
proinflammatory effects of the HMBG1 B-box domain 
through competitive inhibition [52, 55, 56]. In addition, 
inhibitors include cholinergic agents, ethyl pyruvate, 
nicotine, stearoyl lysophosphatidylcholine, and a number of 
Chinese herbs [55, 57, 58]. Recently, the flavinoid quercetin, 
a molecule class well known to potentiate the chloride 
channel function of CFTR, reduced circulating levels of 
HMGB1 in experimental mice with endotoxemia, an effect 
recapitulated in macrophage cultures [59]. Similarly, 
minocycline, a semisynthetic tetracycline, decreased 
HMGB1 expression in microglia cells, and was associated 
with a cerebroprotective effect in a murine model of 
ischemic injury [60]. 
 Targeting  PGP  in vivo presents numerous opportunities 
and challenges. One potential mechanism to affect PGP 
levels in vivo is to quell the increased protease burden seen 
in CF lung disease. Our previous ex vivo data suggest that 
this is a very potent mechanism by which to modulate PGP; 
despite these results, most synthetic or semisynthetic specific 
MMP inhibitors utilized in clinical trials have either suffered 
from inadequate delivery to affected tissues or significant 
side effect profiles limiting their use [61, 62]. However, our 
ex vivo data also highlighted a significant decrease in PGP 
generation by doxycyline, a tetracycline antibiotic [43]. Thus 
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means to inhibit both PGP and HMGB1 pathways within the 
CF lung, and deserves further exploration. As such, there is 
an ongoing clinical trial in hospitalized CF patients to 
examining the effects of doxycycline as an anti-
inflammatory therapy in CF lung disease which hopes to 
address some of these questions. 
  Another potential way to target PGP is by binding the 
peptide by either an antibody or small molecule. While PGP-
specific depleting antibodies have been developed, the 
difficulties with generation of quantities of antibody for 
successful immunization and potential host hyperimmune 
responsiveness limit their potential usefulness as 
therapeutics. A small peptide, arginine-threonine-arginine 
(RTR) has been developed by our laboratory to physically 
bind PGP in vivo [63]. Recently, RTR was shown to inhibit 
both PGP and chronic LPS-induced pulmonary emphysema 
and right ventricular hypertrophy, suggesting that this 
peptide may be used in treatment of PGP-mediated 
inflammation in clinical disease [64]. Our laboratory has 
recently tested RTR with sputum from CF patients and has 
shown a notable decline in its neutrophil chemotaxis activity 
(Gaggar and Blalock, unpublished observations). 
CONCLUSIONS 
  CF is an inflammatory lung disease characterized by 
intense neutrophilic inflammatory response. While many 
facets of this immune cascade have been studied, there is 
ongoing interest in delineation of novel effector molecules in 
this condition. The identification of PGP and HMGB1 offers 
a window into further enhancing our understanding of CF-
related airway inflammation and highlights potential unique 
therapeutic opportunities in this condition. Further studies 
are needed to clarify the relative contributions that these 
molecules contribute to CF pathogenesis. 
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ABBREVIATIONS 
APE  =  Acute pulmonary exacerbation of cystic  
     fibrosis 
ASL  =  Airway surface liquid 
BAL =  Bronchoalveolar  lavage 
CF =  Cystic  fibrosis 
CFTR  =  Cystic Fibrosis Transmembrane conductance  
     Regulator 
COPD  =  Chronic obstructive pulmonary disease 
CXC =  Cysteine-x-cysteine 
CXCR =  Cysteine-x-cysteine  receptors 
DNA =  Deoxyribonucleic  acid 
ECM =  Extracellular  matrix 
ELR =  Glutamate-leucine-arginine 
ENaC  =  Epithelial sodium channel 
FEV1  =  Forced expiratory volume 1 second 
HMGB1  =  High moblilty group protein-1 
IL =  Interleukin 
LIX  =  LPS-induced CXC chemokine 
LPS =  Lipopolysaccharide 
MMP =  Matrix  metalloprotease 
N--PGP = Acetylated  PGP 
PE =  Prolyl  endopeptidase 
PGP =  Proline-glycine-proline 
PMN =  Polymorphonuclear  cells 
RAGE  =  Receptor for advanced glycation end-products 
SLE =  Systemic  lupus  erythematosus 
TLR =  Toll-like  receptors 
TNF-  =  Tumor necrosis factor-alpha 
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